Protalix Announces FDA Investigational New Drug Clearance to Commence Once-Monthly Dosing Study of Pegunigalsidase Alfa (PRX-102) for the Treatment of Fabry Disease

CARMIEL, Israel, May 09, 2017 (GLOBE NEWSWIRE) -- Protalix BioTherapeutics, Inc. (NYSE MKT:PLX) (TASE:PLX), announced today that the U.S. Food and Drug Administration (FDA) cleared an Investigational New Drug application (IND) for a clinical trial...
Source: Drugs.com - Clinical Trials - Category: Pharmaceuticals Source Type: clinical trials